390 related articles for article (PubMed ID: 25780283)
21. [Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].
Nozawa K; Watanabe T
Gan To Kagaku Ryoho; 2010 May; 37(5):791-4. PubMed ID: 20495308
[TBL] [Abstract][Full Text] [Related]
22. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
Fabian P; Berkovcová J
Cesk Patol; 2011 Oct; 47(4):154-8. PubMed ID: 22145213
[TBL] [Abstract][Full Text] [Related]
23. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
Van Cutsem E; Lenz HJ; Köhne CH; Heinemann V; Tejpar S; Melezínek I; Beier F; Stroh C; Rougier P; van Krieken JH; Ciardiello F
J Clin Oncol; 2015 Mar; 33(7):692-700. PubMed ID: 25605843
[TBL] [Abstract][Full Text] [Related]
24. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
[TBL] [Abstract][Full Text] [Related]
25. Should oncologists be aware in their clinical practice of KRAS molecular analysis?
Santini D; Galluzzo S; Gaeta L; Zoccoli A; Riva E; Ruzzo A; Vincenzi B; Graziano F; Loupakis F; Falcone A; Muda AO; Tonini G
J Clin Oncol; 2011 Mar; 29(8):e206-7; author reply e208-9. PubMed ID: 21263083
[No Abstract] [Full Text] [Related]
26. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
Bardelli A; Siena S
J Clin Oncol; 2010 Mar; 28(7):1254-61. PubMed ID: 20100961
[TBL] [Abstract][Full Text] [Related]
27. Letter to the editor: Worse prognosis caused by anti-EGFR treatment in advanced colorectal cancer patients with KRAS mutation.
Yin P; Qiu Y; Li Q
Int J Colorectal Dis; 2013 May; 28(5):733-4. PubMed ID: 22752244
[No Abstract] [Full Text] [Related]
28. Personalized medicine and anti-EGFR antibody therapy in the treatment of metastatic colorectal cancer: KRAS and beyond.
Chu E
Oncology (Williston Park); 2014 Feb; 28(2):96. PubMed ID: 24701695
[No Abstract] [Full Text] [Related]
29. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
30. Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer.
Huang F; Xu LA; Khambata-Ford S
Clin Cancer Res; 2012 Feb; 18(4):1156-66. PubMed ID: 22294722
[TBL] [Abstract][Full Text] [Related]
31. First-Line Treatment of Metastatic Colorectal Cancer: Interpreting FIRE-3, PEAK, and CALGB/SWOG 80405.
Elez E; Argilés G; Tabernero J
Curr Treat Options Oncol; 2015 Nov; 16(11):52. PubMed ID: 26374340
[TBL] [Abstract][Full Text] [Related]
32. KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents.
Bekaii-Saab T
Clin Colorectal Cancer; 2009 Jul; 8(3):135-40. PubMed ID: 19632927
[TBL] [Abstract][Full Text] [Related]
33. KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer.
Baynes RD; Gansert J
Am J Ther; 2009; 16(6):554-61. PubMed ID: 19352138
[TBL] [Abstract][Full Text] [Related]
34. Morphological and molecular heterogeneity in colorectal neoplasms with K-RAS mutation. A report of two cases.
Bösmüller H; Kranewitter W; Webersinke G; Rumpold H; Hackl M; Fend F
Pathol Res Pract; 2011 Jun; 207(6):399-402. PubMed ID: 21536390
[TBL] [Abstract][Full Text] [Related]
35. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
Selcukbiricik F; Erdamar S; Ozkurt CU; Molinas Mandel N; Demirelli F; Ozguroglu M; Tural D; Buyukunal E; Serdengecti S
J BUON; 2013; 18(1):116-23. PubMed ID: 23613396
[TBL] [Abstract][Full Text] [Related]
36. KRAS mutation testing in colorectal cancer.
Plesec TP; Hunt JL
Adv Anat Pathol; 2009 Jul; 16(4):196-203. PubMed ID: 19546608
[TBL] [Abstract][Full Text] [Related]
37. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.
de Reyniès A; Boige V; Milano G; Faivre J; Laurent-Puig P
J Clin Oncol; 2008 May; 26(13):2228-30; author reply 2230-1. PubMed ID: 18445856
[No Abstract] [Full Text] [Related]
38. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
Rizzo S; Bronte G; Fanale D; Corsini L; Silvestris N; Santini D; Gulotta G; Bazan V; Gebbia N; Fulfaro F; Russo A
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S56-61. PubMed ID: 21129611
[TBL] [Abstract][Full Text] [Related]
39. EGFR antibodies in colorectal cancer: where do they belong?
Grothey A
J Clin Oncol; 2010 Nov; 28(31):4668-70. PubMed ID: 20921457
[No Abstract] [Full Text] [Related]
40. Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients.
Guinney J; Ferté C; Dry J; McEwen R; Manceau G; Kao KJ; Chang KM; Bendtsen C; Hudson K; Huang E; Dougherty B; Ducreux M; Soria JC; Friend S; Derry J; Laurent-Puig P
Clin Cancer Res; 2014 Jan; 20(1):265-272. PubMed ID: 24170544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
